SCHEMBL1711030

SCHEMBL1711030

O=C(O)c1ccc(NCc2ccccc2)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 5/20 0.59
HDAC1 Q13547 4/20 0.59
HDAC6 Q9UBN7 4/20 0.59
L3MBTL1 Q9Y468 2/20 0.55
ALDH1A1 P00352 2/20 0.55
POLB P06746 1/20 0.55
HPGD P15428 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CTDSP1 Q9GZU7 1/20 0.55
MRGPRX4 Q96LA9 1/20 0.51
KDM4E B2RXH2 2/20 0.50
ASPH Q12797 1/20 0.50
RIOX2 Q8IUF8 1/20 0.50
KDM8 Q8N371 1/20 0.50
CYP3A4 P08684 1/20 0.50
PTGFR P43088 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4C Q9H3R0 2/20 0.49
KDM6B O15054 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20401097 0.87 PTGFR (0.53) HDAC8HDAC1HDAC6L3MBTL1ALDH1A1
SCHEMBL14044003 0.84 FFAR1 (0.67) L3MBTL1ALDH1A1POLBMRGPRX4KDM4E
SCHEMBL20236173 0.83 POLB (0.54) HDAC8HDAC1HDAC6L3MBTL1ALDH1A1
SCHEMBL693716 0.83 ALDH1A1 (0.69) HDAC8HDAC1HDAC6L3MBTL1ALDH1A1
SCHEMBL6844762 0.81 L3MBTL1 (0.55) HDAC8HDAC1HDAC6L3MBTL1ALDH1A1
SCHEMBL7993941 0.81 GAA (0.65) HDAC8HDAC1HDAC6L3MBTL1ALDH1A1
SCHEMBL30535169 0.81 GAA (0.65) HDAC8HDAC1HDAC6L3MBTL1ALDH1A1
SCHEMBL20400797 0.79 KDM4C (0.50) HDAC8HDAC1HDAC6ALDH1A1POLB
SCHEMBL12949656 0.79 L3MBTL1 (0.52) HDAC8HDAC1HDAC6L3MBTL1ALDH1A1
SCHEMBL5203429 0.78 SHMT2 (0.56) HDAC8HDAC1HDAC6L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 HDAC8 2097/4885HDAC1 763/4885HDAC6 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.